Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2025)
Cabaletta Bio (CABA) recorded quarterly Income from Continuing Operations of 41840000.0 in Q4 2025, up 7.77% quarter-over-quarter from 45364000.0 in Q3 2025, and down 28.4% on a YoY basis from 58434692.27 in Q4 2024.
Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Cabaletta Bio's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 41840000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 28.4% year-over-year to 41840000.0; the TTM figure through Dec 2025 stood at 168214000.0 (down 45.18% YoY), while the FY2025 annual figure was 168214000.0, down 45.18% from the prior year.
- Income from Continuing Operations was 41840000.0 for Q4 2025 at Cabaletta Bio, up from 45364000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9702000.0 in Q1 2021 to a low of 45364000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 22550850.0 across 5 years, with a median of 16151000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations climbed 1.15% in 2022, then tumbled 90.53% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 13888000.0 in 2021, then fell by 12.99% to 15692000.0 in 2022, then tumbled by 33.1% to 20886000.0 in 2023, then tumbled by 56.02% to 32586000.0 in 2024, then fell by 28.4% to 41840000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 41840000.0 (Q4 2025), 45364000.0 (Q3 2025), and 45067000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - | -41.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.84 Mn |
| Sep 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.07 Mn |
| Mar 31, 2025 | -35.94 Mn |
| Dec 31, 2024 | -32.59 Mn |
| Sep 30, 2024 | -30.63 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -25.05 Mn |
| Dec 31, 2023 | -20.89 Mn |
| Sep 30, 2023 | -16.45 Mn |
| Jun 30, 2023 | -14.49 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -11.43 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Mar 31, 2022 | -12.95 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -11.56 Mn |
| Jun 30, 2021 | -11.14 Mn |
| Mar 31, 2021 | -9.70 Mn |